Active Substance: ranibizumab
Common Name: ranibizumab
ATC Code: S01LA04
Marketing Authorisation Holder: Novartis Europharm Ltd
Active Substance: ranibizumab
Authorisation Date: 2007-01-22
Therapeutic Area: Wet Macular Degeneration Macular Edema Myopia, Degenerative Diabetes Complications
Pharmacotherapeutic Group: Ophthalmologicals
Lucentis is indicated in adults for:
- the treatment of neovascular (wet) age-related macular degeneration (AMD);
- the treatment of visual impairment due to diabetic macular oedema (DME);
- the treatment of visual impairment due to macular oedema secondary to retinal-vein occlusion (branch RVO or central RVO);
- the treatment of visual impairment due to choroidal neovascularisation (CNV) secondary to pathologic myopia (PM).
What is Lucentis?
Lucentis is a medicine that contains the active substance ranibizumab. It is available as a solution for injection in prefilled syringes or vials.
What is Lucentis used for?
Lucentis is used to treat adults with:
- the ‘wet’ form of age-related macular degeneration (AMD), a disease which affects the central part of the retina (called the macula) at the back of the eye. The wet form of AMD is caused by choroidal neovascularisation ( abnormal growth of blood vessels beneath the retina) under the macula, which may leak fluid and blood and cause swelling;
- macular oedema (swelling of the macula) caused by diabetes;
- macular oedema caused by occlusion (blockage) of the veins behind the retina;
- choroidal neovascularisation caused by pathologic myopia (a severe type of short-sightedness where the eyeball continues to grow, becoming longer than it should be).
The macula provides central vision needed to see detail for everyday tasks such as driving, reading and recognising faces. The swelling and damage due to these diseases cause the gradual loss of this central vision.
The medicine can only be obtained with a prescription.
How is Lucentis used?
Lucentis must be given as an intravitreal injection (injection into the vitreous humour, the jelly-like fluid in the eye) by a qualified eye doctor who is experienced in giving intravitreal injections.
The recommended dose for Lucentis is 0.5 mg given as a single intravitreal injection. The procedure should be carried out under sterile conditions. The syringe and the vial are for single use only. The prefilled syringe contains more than the recommended dose, therefore when preparing the injection, the doctor must expel the excess volume and ensure the injection of the correct dose.
Treatment with Lucentis is started with one injection every month, with regular checks of the patient’s vision and the appearance of the back of the eye, until maximum vision is achieved and/or there are no signs of disease activity; the monitoring and treatment intervals should then be determined by the treating doctor. Treatment with Lucentis should be stopped if the patient is not benefitting from it.
For wet AMD and macular oedema, three or more consecutive monthly injections may be needed initially. For choroidal neovascularisation caused by pathological myopia, many patients may only need one or two injections during the first year of treatment, while some patients may need more frequent treatment.
The interval between two injections of Lucentis into the same eye must be at least four weeks. Before each injection, a local anaesthetic is given to reduce or prevent any pain from the injection, and the eye, eyelid and skin around the eye are disinfected.
For more information, see the package leaflet.
How does Lucentis work?
The active substance in Lucentis, ranibizumab, is a small piece of a monoclonal antibody. A monoclonal antibody is an antibody (a type of protein) that has been designed to recognise and attach to a specific structure (called an antigen) that is found in certain cells in the body.
Ranibizumab has been designed to block a substance called vascular endothelial growth factor A (VEGF‑A). VEGF‑A is a protein that makes blood vessels grow and leak fluid and blood. These effects worsen the damage to the macula. By blocking this factor, ranibizumab reduces the growth of the blood vessels and controls the leakage and swelling.
How has Lucentis been studied?
Three main studies of Lucentis involved 1,323 patients with the wet form of AMD. All of the patients were over 50 years of age and had not been treated for wet AMD before. Two of the studies compared Lucentis with a sham injection. This is a procedure that is similar to a Lucentis injection, but with no Lucentis and no needle, in which the syringe is pressed against the surface of the eye but no actual injection is carried out. The patients cannot tell whether they received Lucentis or the sham procedure. The third study compared Lucentis with verteporfin photodynamic therapy (PDT, another treatment for AMD). The main measure of effectiveness was the change in vision in the affected eye after a year of treatment, using a standard eye test with a letter chart. Patients were classified as having experienced no significant worsening of vision if the number of letters that they could see increased, stayed the same, or fell by less than 15.
For diabetic macular oedema, Lucentis was studied in two main studies involving a total of 454 patients. The first study compared Lucentis with a sham injection. The second study compared Lucentis, given on its own or as an add-on to laser photocoagulation (a treatment for diabetic macular oedema using a laser), with laser photocoagulation on its own. For macular oedema due to retinal vein occlusion, Lucentis was looked at in two main studies involving a total of 789 patients, where Lucentis was compared with a sham injection. In all studies, the main measure of effectiveness was the change in vision in the affected eye, measured by comparing the number of letters that the patient could see at the end of the treatment period with the number before starting treatment.
For choroidal neovascularisation due to pathologic myopia, Lucentis was compared with verteporfin PDT in one main study involving 277 patients. The main measure of effectiveness was the change in vision seen in the first 3 months of treatment, using a standard eye test with a letter chart.
What benefit has Lucentis shown during the studies?
In AMD, Lucentis was more effective at preventing a worsening of vision than its comparators. Between 94 and 96% of the AMD patients receiving Lucentis every month experienced no significant worsening of their vision, compared with 62% of those receiving sham injections and 64% of those treated with verteporfin PDT. The vision of patients receiving Lucentis also remained better than the vision of those receiving sham injections in a study in which injections were given less frequently, with injections every month for the first three months and then every three months.
In diabetic macular oedema, Lucentis was more effective at improving vision than its comparators. In the first study, after one year, patients receiving Lucentis could see about 6 letters more than those receiving sham injections. In the second study, patients receiving Lucentis on its own or as an add‑on to laser photocoagulation could see after one year an average of 5 letters more than patients receiving laser photocoagulation on its own. In macular oedema due to retinal vein occlusion, Lucentis was more effective than a sham injection: patients receiving Lucentis at the 0.5 mg dose for six months could see around 11 letters more than patients receiving a sham injection in one study and 14 letters more in another study.
In choroidal neovascularisation due to pathologic myopia, on average in the first 3 months of treatment, patients given Lucentis could see around 8-9 letters more than those receiving verteporfin PDT.
What is the risk associated with Lucentis?
The most common side effects with Lucentis (seen in more than 1 in 10 patients) are increased intraocular pressure (pressure within the eye), headache, vitritis (inflammation in the eye), vitreous detachment (separation of the vitreous from the back of the eye), retinal haemorrhage (bleeding at the back of the eye), visual disturbance, eye pain, vitreous floaters (spots in the vision), conjunctival haemorrhage (bleeding at the front of the eye), eye irritation, sensation of a foreign body in the eye, increased lacrimation (tear production), blepharitis (inflammation of the eyelids), dry eye, ocular hyperaemia (red eye), eye pruritis (itching), arthralgia (joint pain) and nasopharyngitis (inflammation of the nose and throat). Rarely, endophthalmitis (an infection inside the eye), blindness, serious damage to the retina and cataract (clouding of the lens) can occur. For the full list of all side effects reported with Lucentis, see the package leaflet.
Lucentis must not be used in patients who may have an infection of the eye or the area around the eye, or who have severe inflammation within the eye.
For the full list of restrictions, see the package leaflet.
Why has Lucentis been approved?
The CHMP decided that Lucentis’s benefits are greater than its risks and recommended that it be given marketing authorisation.
What measures are being taken to ensure the safe and effective use of Lucentis?
A risk management plan has been developed to ensure that Lucentis is used as safely as possible. Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Lucentis, including the appropriate precautions to be followed by healthcare professionals and patients.
In addition, the company that makes Lucentis will provide all clinics where Lucentis is expected to be used with information packs for doctors (including information on the measures needed to minimise the risk of infection associated with injections into the eye) and packs for patients (to help them prepare for Lucentis treatment, recognise serious side effects and know when to seek urgent attention from their doctor).
Other information about Lucentis
The European Commission granted a marketing authorisation valid throughout the European Union for Lucentis on 22 January 2007.
For more information about treatment with Lucentis, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Source: European Medicines Agency
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.